Skip to Main Content

Paper Details

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Clin Cancer Res
55
2020
ABT-199, BCL2, BCL2 family, CDK4, CDK4/6, ER, ER+, ER+ breast cancer, ER+ breast cancer cell lines, Estrogen, Estrogen Receptor, Estrogen Receptor-Positive Breast Cancer, G1, G1-S cyclins, PDO, Rb, Tumor, anti-PD1, breast cancer, cyclin-dependent kinase 4 and 6, estrogen, estrogen receptor, estrogen receptor-positive (ER+, fulvestrant, mammary tumor, mouse, palbociclib, patient, patient-derived organoid, patient-derived xenograft (PDX) models, patients, senescent cells, syngeneic ER+ mammary tumor model, syngeneic ER+ mouse mammary tumor model, tumor, venetoclax
Author NameAffiliation
James R WhittleThe Walter and Eliza Hall Institute of Medical Research
James R WhittleThe University of Melbourne
James R WhittleThe Peter MacCallum Cancer Centre
James R WhittleThe Walter and Eliza Hall Institute of Medical Research
James R WhittleThe Peter MacCallum Cancer Centre
James R WhittleThe University of Melbourne
Hans CleversOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Centre (UMC)
Hans CleversPrincess Maxima Center for Pediatric Oncology
Gordon K SmythThe Walter and Eliza Hall Institute of Medical Research
Gordon K SmythThe University of Melbourne
Gordon K SmythThe Walter and Eliza Hall Institute of Medical Research
Gordon K SmythThe University of Melbourne
  • 1 - 12

Datasets

Release 1.2